Mercedes Berenguer Piqueras

Sanchez-Villalobos M, Campos Banos E, Juan Fita MJ, Egea Mellado JM, Gonzalez Gallego I, Beltran Videla A, Berenguer Piqueras M, Bermudez Cortes M, Moraleda Jimenez JM, Guillen Navarro E, Salido Fierrez E, Perez-Oliva AB. A Newborn Screening Program for Sickle Cell Disease in Murcia (Spain). Int J Neonatal Screen. 2023 Oct 10;9(4):55. doi: 10.3390/ijns9040055. PubMed PMID: 37873846; PubMed Central PMCID: PMC10594431.

AÑO: 2023

37873846

Vasco-Mogorrón MA, Campillo JA, Periago A, Cabañas V, Berenguer M, García-Garay MC, Gimeno L, Soto-Ramírez MF, Martínez-Hernández MD, Muro M, Minguela A. Blood-based risk stratification for pre-malignant and symptomatic plasma cell neoplasms to improve patient management. Am J Cancer Res. 2021 Jun 15;11(6):2736-2753. eCollection 2021. PubMed PMID: 34249425; PubMed Central PMCID: PMC8263680.

AÑO: 2021; IF: 5.942

34249425

Minguela A, Salido EJ, Soto-Ramírez MF, Olga MA, Leal JD, García-Garay MC, Periago A, Berenguer M, Blanque M, Campillo JA. Low-affinity immunoglobulin gamma Fc region receptor III-B (FcγRIIIB, CD16B) deficiency in patients with blood and immune system disorders. Br J Haematol. 2021 Dec;195(5):743-747. doi: 10.1111/bjh.17828. Epub 2021 Sep 20. PubMed PMID: 34544201.

AÑO: 2021; IF: 8.615

34544201

Minguela A, Vasco-Mogorrón MA, Campillo JA, Cabañas V, Remigia MJ, Berenguer M, García-Garay MC, Blanquer M, Cava C, Galian JA, Gimeno L, Soto-Ramírez MF, Martínez-Hernández MD, de la Rubia J, Teruel AI, Muro M, Periago A. Predictive value of 1q21 gain in multiple myeloma is strongly dependent on concurrent cytogenetic abnormalities and first-line treatment. Am J Cancer Res. 2021 Sep 15;11(9):4438-4454. eCollection 2021. PubMed PMID: 34659897; PubMed Central PMCID: PMC8493371.

AÑO: 2021; IF: 5.942

34659897

Vasco-Mogorrón MA, Campillo JA, Periago A, Cabañas V, Berenguer M, García-Garay MC, Gimeno L, Soto-Ramírez MF, Martínez-Hernández MD, Muro M, Minguela A. Proliferation to Apoptosis Tumor Cell Ratio as a Biomarker to Improve Clinical Management of Pre-Malignant and Symptomatic Plasma Cell Neoplasms. Int J Mol Sci. 2021 Apr 9;22(8). pii: 3895. doi: 10.3390/ijms22083895. PubMed PMID: 33918790; PubMed Central PMCID: PMC8068942.

AÑO: 2021; IF: 6.208

33918790